Omalizumab retreatment in patients with chronic spontaneous urticaria:a systematic review of published evidence
Abstract
A systematic review of the current literature on retreatment with omalizumab of patients with relapsing chronic spontaneous urticaria was performed.Published evidence shows that retreatment is safe and clinically effective, and that time to complete clinical response reduces as the number of retreatments increases.to four times the licensed antihistamine dose may be beneficial, but around 45% of patients fail to respond (5).For these cases, omalizumab is recommended as add-on therapy, as third-line treatment option.Omalizumab is a humanized monoclonal antibody recognizing the Fc portion of the immunoglobulin E (IgE) molecule.It is thought to reduce IgE-and FcεRI-mediated mast cell and basophil activation (6,7), with a similar outcome on both mast cells and basophils.Launched around 20 years ago to treat patients with severe asthma non responsive to standard treatment, it is currently used in several other allergic conditions including refractory CSU since 2013, displaying high efficacy and safety, especially when compared to first-and second-line therapies.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.